Hypertension is a risk factor for atherosclerosis. Achieving the therapeutic target value of blood pressure (BP) prevents the onset of cardiovascular events; however, it is not clear how antihypertensive drug use and BP control status relate to arterial stiffness. The purpose of this study is to investigate the relationship between BP control status with or without antihypertensive drugs and arterial stiffness. Nine hundred eighty individuals (mean age: 68 ± 11 years) who participated in a community-based cohort study were enrolled. Arterial stiffness was evaluated using the cardio-ankle vascular index (CAVI). Higher BP was defined as a systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg. Participants were divided into four groups: normal, non higher BP without antihypertensive drugs (n = 421); untreated, higher BP without antihypertensive drugs (n = 174); good control, non higher BP with antihypertensive drugs (n = 209); and poor control, higher BP with antihypertensive drugs (n = 176). In multivariable logistic analysis adjusted for age, sex, dyslipidemia and diabetes mellitus medication use, obesity, smoking, alcohol drinking, and heart rate at the CAVI measurement for a high CAVI—using a borderline cutoff value of 8.0—the other three groups were significantly associated with a high CAVI when compared with the normal group. By contrast, multivariable logistic analysis of a high CAVI using an abnormal cutoff value of 9.0 demonstrated that the poor control and untreated groups were significantly associated with a high CAVI, whereas the good control group was not. In conclusion, even with antihypertensive drugs, poor BP control is independently associated with a high CAVI.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update From the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982–3021.
Ikeda N, Inoue M, Iso H, Ikeda S, Satoh T, Noda M, et al. Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan: A comparative risk assessment. PLoS Med. 2012;9:e1001160.
Saiki A, Sato Y, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, et al. The role of a novel arterial stiffness parameter, cardio-ankle vascular index (CAVI), as a surrogate marker for cardiovascular diseases. J Atheroscler Thromb. 2016;23:155–68.
Fujiyoshi A, Ohkubo T, Miura K, Murakami Y, Nagasawa SY, Okamura T, et al. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res. 2012;35:947–53.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285–95.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.
Brunström M, Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178:28–36.
SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103–16.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.
Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011;18:924–38.
Kubozono T, Miyata M, Ueyama K, Nagaki A, Otsuji Y, Kusano K, et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J. 2007;71:89–94.
Ueyama K, Miyata M, Kubozono T, Nagaki A, Hamasaki S, Ueyama S, et al. Noninvasive indices of arterial stiffness in hemodialysis patients. Hypertens Res. 2009;32:716–20.
Ibata J, Sasaki H, Hanabusa T, Wakasaki H, Furuta H, Nishi M, et al. Increased arterial stiffness is closely associated with hyperglycemia and improved by glycemic control in diabetic patients. J Diabetes Investig. 2013;4:82–7.
Namekata T, Suzuki K, Ishizuka N, Shirai K. Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study. BMC Cardiovasc Disord. 2011;11:51.
Kubozono T, Miyata M, Ueyama K, Hamasaki S, Kusano K, Kubozono O, et al. Acute and chronic effects of smoking on arterial stiffness. Circ J. 2011;75:698–702.
Nagayama D, Yamaguchi T, Saiki A, Imamura H, Sato Y, Ban N, et al. High serum uric acid is associated with increased cardio-ankle vascular index (CAVI) in healthy Japanese subjects: a cross-sectional study. Atherosclerosis. 2015;239:163–8.
Ishida K, Morimoto S, Horiuchi S, Kimura M, Ishikawa T, Kimura S, et al. Comparison of the usefulness of the cardio-ankle vascular index and augmentation index as an index of arteriosclerosis in patients with essential hypertension. Hypertens Res. 2022;45:455–63.
Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J. 2008;72:598–604.
Miyoshi T, Ito H, Shirai K, Horinaka S, Higaki J, Yamamura S, et al. Predictive value of the cardio‐ankle vascular index for cardiovascular events in patients at cardiovascular risk. J Am Heart Assoc. 2021;10:e020103.
Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, et al. Cardio-ankle vascular index is independently associated with future cardiovascular events in outpatients with metabolic disorders. J Atheroscler Thromb. 2016;23:596–605.
Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, et al. Physiological diagnostic criteria for vascular failure. Hypertension. 2018;72:1060–71.
Ojima S, Kubozono T, Kawasoe S, Kawabata T, Miyata M, Miyahara H, et al. Association of risk factors for atherosclerosis, including high-sensitivity C-reactive protein, with carotid intima-media thickness, plaque score, and pulse wave velocity in a male population. Hypertens Res. 2020;43:422–30.
Inoue T, Matsuoka M, Shinjo T, Tamashiro M, Oba K, Kakazu M, et al. Blood pressure, frailty status, and all-cause mortality in elderly hypertensives; The Nambu Cohort Study. Hypertens Res. 2022;45:146–54.
Otsuka K, Fukuda S, Shimada K, Suzuki K, Nakanishi K, Yoshiyama M, et al. Serial assessment of arterial stiffness by cardio-ankle vascular index for prediction of future cardiovascular events in patients with coronary artery disease. Hypertens Res. 2014;37:1014–20.
Park HE, Choi SY, Kim MK, Oh BH. Cardio-ankle vascular index reflects coronary atherosclerosis in patients with abnormal glucose metabolism: assessment with 256 slice multi-detector computed tomography. J Cardiol. 2012;60:372–6.
Chung SL, Yang CC, Chen CC, Hsu YC, Lei MH. Coronary Artery Calcium Score Compared with Cardio-Ankle Vascular Index in the Prediction of Cardiovascular Events in Asymptomatic Patients with Type 2 Diabetes. J Atheroscler Thromb. 2015;22:1255–65.
Gohbara M, Iwahashi N, Sano Y, Akiyama E, Maejima N, Tsukahara K, et al. Clinical Impact of the Cardio-Ankle Vascular Index for Predicting Cardiovascular Events After Acute Coronary Syndrome. Circ J. 2016;80:1420–6.
Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239–45.
Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.
Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135:825–34.
Spence JD, Rayner BL. J curve and cuff artefact, and diagnostic inertia in resistant hypertension. Hypertension. 2016;67:32–3.
Milman T, Joundi RA, Alotaibi NM, Saposnik G. Clinical inertia in the pharmacological management of hypertension: A systematic review and meta-analysis. Med (Baltim). 2018;97:e11121.
Mitchell GF. Arterial stiffness and hypertension: chicken or egg? Hypertension. 2014;64:210–4.
Miyashita Y, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb. 2009;16:621–6.
Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res. 2009;32:962–8.
We would like to thank the staff of Tarumizu City Office and all researchers of the Tarumizu study for their cooperation in this study.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kawabata, T., Kubozono, T., Ojima, S. et al. Insufficient blood pressure control is independently associated with increased arterial stiffness. Hypertens Res 45, 1861–1868 (2022). https://doi.org/10.1038/s41440-022-01039-3
- Antihypertensive agents
- Blood pressure
- Risk factors
- Vascular stiffness
This article is cited by
Hypertension Research (2022)
Hypertension Research (2022)